Arovella Therapeutics Ltd has released a press release.
SUDA appoints new cell and gene therapy manufacturing expert
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Disclosure Document Prospectus $3.65m
- SUDA Placement Raises $3.65m
- Investor Presentation incorporating iNKT Cell Platform
- SUDA Licenses a Novel iNKT Cell Therapy Platform
- Investor Presentation March 2021
Later from Arovella Therapeutics
- iNKT cell therapy platform update
- ZolpiMist Update
- SUDA signs Licence and Distribution Agreement with STADA
- Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
- GM presentation
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics